# Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Source: https://onco.cc/trials/nct07450183/  
OnCo record `nct07450183` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cemiplimab in lung cancer, run by Henry Ford Health System, not yet recruiting.

## Summary

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 is a phase 2, interventional study registered as NCT07450183 by Henry Ford Health System, with a registry enrolment figure of 33 participants, started 2027-01-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Cemiplimab; Adjuvant chemotherapy. Conditions listed: Lung Cancer (NSCLC). Primary outcome: Pathologic Complete Response Rate. Lung eligibility wording from the registry: "* Patient diagnosed with early-stage resectable stage II to IIIA squamous or non-squamous, operable treatment naïve NSCLC with PD-L1 TPS ≥50%". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07450183
- Phase: 2
- Setting: Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
- Sponsor: Henry Ford Health System
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT07450183: https://clinicaltrials.gov/study/NCT07450183

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07450183.json